GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Adial Pharmaceuticals ADIL · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.05

+36.12%

Close of 28 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$8.0m

FY2016FY2025

Free cash flow

−$6.5m

FY2016FY2025

Shareholders' equity

$5.3m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−$565−$565−$564−$60,501−$55,106−$564−$565−$563−$565−$565
Research and development$2.6m$3.2m$1.3m$2.0m$8.4m$5.9m$4.0m$368,459$182,107$146,143
Operating income−$7.8m−$8.3m−$6.9m−$10.9m−$19.3m−$10.9m−$8.2m−$7.0m−$995,286−$410,797
Net income−$8.0m−$13.2m−$7.0m−$12.7m−$19.4m−$10.9m−$8.6m−$11.6m−$1.1m−$420,200
Diluted earnings per share-7.18-17.75-4.21-298.16-585.04-472.20-505.38-1,097.30-129.48-54.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$6.8m$5.0m$4.7m$5.7m$7.6m$5.5m$7.7m$4.7m$34,546$151,526
Cash and short-term investments$5.9m$3.8m$2.8m$4.0m$6.1m$4.4m$6.8m$3.9m$18,248$87,993
Total liabilities$1.5m$975,858$653,513$2.5m$4.1m$1.5m$539,051$257,974$1.0m$255,019
Debt———$207,375$256,960———$689,265$234,255
Shareholders' equity$5.3m$4.1m$4.1m$3.3m$3.5m$4.0m$7.1m$4.4m−$997,553−$103,493
Shares outstanding1m1m2m0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$6.5m−$6.9m−$6.8m−$11.2m−$11.9m−$7.6m−$6.3m−$2.5m−$494,862−$274,384
Capital spending−$3—−$6.8m−$5−$64,605−$64,605−$64,605−$64,605——
Free cash flow−$6.5m−$6.9m−$13.6m−$11.2m−$12.0m−$7.7m−$6.4m−$2.6m−$494,862−$274,384

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$564—
Gross profit−$46.2m−$141−$142−$141−$141−$141−$141−$142
Operating income−$52.0m−$2.0m−$1.9m−$1.8m−$1.9m−$2.3m−$1.9m−$2.2m
Net income−$52.0m−$2.0m−$2.0m−$1.8m−$2.0m−$2.2m−$2.1m−$2.2m
Diluted earnings per share-11.25-0.44-1.80-1.61-1.76-2.01-2.78-2.95
Cash from operations−$6.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m−$1.0m
Total assets$29.1m$5.2m$6.8m$5.7m$6.8m$3.5m$5.0m$6.7m
Cash and short-term investments$28.7m$4.6m$5.9m$4.6m$5.9m$2.4m$3.8m$5.2m
Shareholders' equity$156,000$3.7m$5.3m$4.5m$5.6m$2.1m$4.1m$5.9m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-10.4%-6.5%25.3%
Net income-14.4%-6.0%25.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-0.8-1.4-11.1-0.5-1.5-1.2-1.6-1.6

Share price return

Finished calendar years

20252024202320222021202020192018
Return-77%-34%-73%-82%45%-20%-25%-24%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 6 Feb 2026
  • 25-to-1 reverse split · 7 Aug 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.